Therapeutic method
AssigneeMacfarlane Burnet Institute for Medical Research and Public Health Pty Ltd
InventorsGilda Tachedjian, Anna Hearps
Life of this patent
Estimating the term…
Abstract
The present invention relates generally to a method of down-regulating an inflammatory response in a mammal and to agents useful for same. More particularly, the present invention relates to a method of down-regulating an inflammatory response in the reproductive tract or external genital tissue of a female mammal by contacting the mucosal tissue of the reproductive tract and/or genitalia with lactic acid and to agents useful for same. The method of the present invention is useful, inter alia, in the treatment and/or prophylaxis of conditions characterised by an aberrant, unwanted or otherwise inappropriate inflammatory response including, for example, atrophic vaginitis, irritant vaginitis or infectious vaginitis.
Claims15
A method for down-regulating inflammation in the reproductive tract or genital tissue of a female mammal said method comprising mucosally administering a composition comprising an organic acid having the formula (I) or in vivo hydrolysable esters or phosphate esters and salts thereof (I):
- wherein n is an integer from 0 to 10;
- wherein Pr is hydrogen or an in vivo hydrolysable protecting group;
- and
- wherein the compound is in the form of a racemate, enantiomer or a mixture of enantiomers and wherein said mucosa is contacted with an effective concentration of approximately 0.1%-1.9% v/v of said organic acid.
A method of therapeutically or prophylactically treating a condition characterised by an aberrant, unwanted or otherwise inappropriate inflammatory response in the reproductive tract or the genital tissue of a female mammal said method comprising mucosally administering a composition comprising an organic acid having the formula (I) or in vivo hydrolysable esters or phosphate esters and salts thereof:
- wherein n is an integer from 0 to 10;
- wherein Pr is hydrogen or an in vivo hydrolysable protecting group;
- and
- wherein the compound is in the form of a racemate, enantiomer or a mixture of enantiomers and wherein said mucosa is contacted with an effective concentration of approximately 0.1%-1.9% v/v of said organic acid.
A pharmaceutical composition comprising an organic acid having the formula (I) or in vivo hydrolysable esters or phosphate esters and salts thereof:
- wherein n is an integer from 0 to 10;
- wherein Pr is hydrogen or an in vivo hydrolysable protecting group;
- and
- wherein the compound is in the form of a racemate, enantiomer or a mixture of enantiomers together with one or more pharmaceutically acceptable carriers and/or diluents.
Dependencies are inferred from the claim text.